EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

A COMPARATIVE STUDY OF HORMONE RECEPTOR EXPRESSION IN BREAST CARCINOMA PATIENTS

Dr. Supriya and Dr. Vijay Verma*

ABSTRACT

Background: Cancer of breast is the most common cancer affecting women worldwide, and is the second most common cause of cancer death next to lung cancer. Breast cancer is the most common malignancy in women and is the leading cause of cancer mortality worldwide. It is responsible for more than 500,000 deaths annually. In urban Indian population breast carcinoma is the most common cancer among women. The incidence of carcinoma breast patients has increased over a period of few years, reason being either increased awareness or early diagnosis. Hormone receptor status of a given breast cancer (ER, PR) provides information about the particular genetic type of cells which have become malignant and an indication of how the breast carcinoma will likely respond to chemotherapy and endocrine therapy (hormone related therapy) if required. Her2neu is a tumour biomarker associated with disease progression and metastatic potential. Ki67 is a proliferation marker which shows how fast the tumour is growing, whether or not there is evidence of cell damage and death. The tumors that are estrogen receptor (ER) positive and/or progesterone receptor (PR) positive have lower risks of mortality after their diagnosis compared to women with ER and/or PR-negative disease. Material and methods: Hormone receptor expression (ER, PR, HER2NEU and KI67) was studied in fifty patients of carcinoma breast, and also compared with similar studies in various parts of the world. Results: The result of our study reveals that the carcinoma breast patients of this region have more ER, PR and HER2NEU negativity which is different from that of other parts of the world. Also, KI positivity below 10% is predominant in our study which correlates with the worse prognosis of this disease. Conclusion: Carcinoma breast patients of this part of the subhimalayan region vary in hormone receptor expression, tumour subtype and age of diagnosis from that of other parts of the world.

Keywords: triple negative breast cancer, estrogen receptor, progesterone receptor, HER2NEU receptor.

[Full Text Article] [Download Certificate]